Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The University of Edinburgh, in collaboration with the SNBTS, Roslin Institute Neuropathogenesis Unit, and the University of Strathclyde, has developed an antibody that can distinguish abnormal PrP (PrPSc) from the normal cellular form (PrPC) More
Monoclonal antibody for a novel HIV protein with potential diagnostic, prognostic, and therapeutic uses. More
We have developed an indirect ELISA that it is able to differentiate between animals infected with C. abortus from those infected with C. pecorum More
Novel anti-HIV human monoclonal antibody exhibits a unique binding activity compared to its counterparts. More
Adrenomedullin peptides and antibodies, which would be useful in the development of a therapeutic or for diagnostics use More
A monoclonal antibody that recognises a sub-population of neutrophils that are believed to be in the ‘late’ stages of apoptosis More
A monoclonal antibody that recognises a glycoprotein of unknown function on the surface of apoptotic neutrophils More
A variety of new toxoids useful as botulinum vaccine antigens, for BAT or BIG production, or for development of tests to evaluate antigenicity of botulinum vaccines More
Hybridoma cell lines capable of expressing monoclonal antibodies against FHA More
Your selection
Browse By
- Therapeutic target
- Bacteria or virus
- Bioterrorism
- Diseases
- Hepatitis (other)
- Nosocomial infections
- Parasitic diseases
- Treatments
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us